Abstract 16P
Background
Radiotherapy plays an important role in the treatment of cases who had breast conserving surgery. Breast cancer patients who receive radiotherapy develop acute skin complications which are known as radiation dermatitis (RD) during radiotherapy or shortly after it. Radiation dermatitis is one of the most common side effects. It affects approximately 95% of patients. This complication has a profound effect on patients' quality of life due to pain and discomfort and can reduce tolerance to treatment and in some cases discontinuation or delay of radiotherapy. This can effect disease control in the long term. So, prevention and treatment of RD is important for health care providers and it is essential to produce effective health products to prevent and treat this disease. Henna (Lawsonia inermis L.) is a medicinal plant which has antimicrobial, anti-inflammatory, and skin-enhancing properties, all of which are useful for people who have radition dermatitis. Also, studies have shown antimicrobial, anti-inflammatory, analgesic, and wound healing effects of henna. This research aimed to evaluate the efficacy of a topical henna preparation (HP) in preventing and reducing the severity of RD in breast cancer patients.
Methods
This was a prospective double-blind clinical study which contained 43 breast cancer patients aged 18-75 years who had breast-conserving surgery and were going to receive radiotherapy. They were randomly allocated into two groups, those who received the topical HP or those who received placebo, twice daily for six weeks, from the first day of treatment. Grade of dermatitis was evaluated weekly based on RTOG grading system.
Results
The present study showed that HP could reduce the severity of RD. The use of HP delayed the onset of grade 2 RD for two weeks, also, it delayed the onset of grade 3 RD for one week compared to the placebo group. At the end of the sixth week, in the patients who received the HP, the grade 2 RD (20% vs. 56.52%) as well as grade 3 RD (10% vs. 26.09%) significantly decreased (p=0.004).
Conclusions
Topical henna cream is an inexpensive and accessible herbal medicine that can be effective in preventing and reducing the severity of RD in patients with breast cancer.
Clinical trial identification
IRCT2019110704537N1.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session
68TiP - KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC
Presenter: Shigehira Saji
Session: e-Poster Display Session
69TiP - MADELINE Asia: A mobile app-based prospective observational study of patient reported outcomes in advanced breast cancer in Asia
Presenter: Anna Tai
Session: e-Poster Display Session
113TiP - Prospective observational study monitoring circulating tumour DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY study in CIRCULATE-Japan
Presenter: Hiroki Yukami
Session: e-Poster Display Session
195TiP - GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Rui-Hua Xu
Session: e-Poster Display Session
196TiP - Perioperative sintilimab in combination with concurrent chemoradiotherapy for patients with locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
Presenter: Jia Wei
Session: e-Poster Display Session
197TiP - A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
Presenter: Shukui Qin
Session: e-Poster Display Session
198TiP - SPOTLIGHT: Phase III study of zolbetuximab + mFOLFOX6 versus placebo + mFOLFOX6 in first-line Claudin18.2⁺/HER2⁻ advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Presenter: Kohei Shitara
Session: e-Poster Display Session
233TiP - Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study
Presenter: Daniel Petrylak
Session: e-Poster Display Session
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session